- Tenon Medical (TNON, Financial) completes initial case series using Catamaran SI Joint Fusion System.
- FDA approval expands system use for sacropelvic fixation in lumbar fusion, unlocking new market opportunities.
- Dr. Andrew J. Trontis leads successful integration, highlighting stability without significant complications.
Tenon Medical, Inc. (TNON) has successfully completed an initial case series utilizing its Catamaran® SI Joint Fusion System. This milestone aims to enhance the stabilization of the sacroiliac (SI) joint during lumbar fusion procedures, performed by Dr. Andrew J. Trontis at Progressive Spine & Orthopaedics in Englewood, New Jersey. The Catamaran system, following its expanded indication approval by the U.S. Food and Drug Administration (FDA), is now permitted to be used in sacropelvic fixation as part of these complex spinal surgeries.
Dr. Trontis emphasized the advantages of integrating the Catamaran system into spinal fusion procedures, stating it provides robust stabilization at the base of the fusion without leading to significant morbidity, additional operative time, or increased blood loss. This integration potentially reduces the risk of future sacroiliac joint pain and pelvic instrumentation failure, which are critical elements for surgeon adoption.
Steven M. Foster, President and CEO of Tenon Medical, highlighted that this expanded indication for the Catamaran system represents a strategic market expansion opportunity for the company. This approval allows Tenon Medical to address both primary SI joint dysfunction and provide adjunctive stabilization, thereby opening substantial new market opportunities within the complex spine surgery sector.
The Catamaran system's expanded use is seen as a method to address biomechanical challenges at the sacropelvic junction during complex spinal fusion operations, positioning Tenon Medical to potentially capture market share in this growing medical field.
